U.S. Markets closed

Today’s Research Reports on IntelliPharmaCeutics, Nuvo Pharmaceuticals, Oncolytics Biotech and Baylin Technologies

NEW YORK, NY / ACCESSWIRE / March 1, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

IntelliPharmaCeutics International Inc.
https://rdinvesting.com/news/?ticker=IPCI.TO

Nuvo Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=NRI.TO

Oncolytics Biotech Inc.
https://rdinvesting.com/news/?ticker=ONC.TO

Baylin Technologies Inc.
https://rdinvesting.com/news/?ticker=BYL.TO

IntelliPharmaCeutics' stock moved 3.66% higher Wednesday, to close the day at $0.85. The stock recorded a trading volume of 12,150 shares, which was below its three months average volume of 35,145 shares. In the last year, IntelliPharmaCeutics' shares have traded in a range of 0.78 - 3.73. The stock is currently trading 77.21% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.97 is below its 200-day moving average of $1.11. Shares of IntelliPharmaCeutics have fallen approximately 14.14 percent year-to-date.

Access RDI's IntelliPharmaCeutics International Inc. Research Report at:
https://rdinvesting.com/news/?ticker=IPCI.TO

On Wednesday, shares of Nuvo Pharmaceuticals’ recorded a trading volume of 5,245 shares, which was below the three months average volume of 12,582 shares. The stock ended the day 4.69% lower at 3.25. The stock is currently trading 47.83% below its 52 week high with a 52 week trading range of 3.21 - 6.23. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $3.62 is below its 200-day moving average of $3.95. Shares of the company are trading at a Price to Earnings ratio of 11.48. Shares of Nuvo Pharmaceuticals have fallen approximately 12.16 percent year-to-date.

Access RDI's Nuvo Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NRI.TO

Oncolytics Biotech's stock jumped 14.29% Wednesday, to close the day at $0.80. The stock recorded a trading volume of 509,445 shares, which was above its three months average volume of 340,900 shares. In the last year, Oncolytics Biotech's shares have traded in a range of 0.36 - 1.13. The share price has gained 122.22% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.78 is greater than its 200-day moving average of $0.66. Shares of Oncolytics Biotech have gained approximately 12.68 percent year-to-date.

Access RDI's Oncolytics Biotech Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ONC.TO

On Wednesday, shares of Baylin Technologies recorded a trading volume of 8,740 shares, which was below the three months average volume of 45,696 shares. The stock ended the day 1.29% lower at 3.84. The share price has gained 105.35% from its 52 week low with a 52 week trading range of 1.87 - 4.12. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $3.71 is greater than its 200-day moving average of $2.67. Shares of Baylin Technologies have gained approximately 11.63 percent year-to-date.

Access RDI's Baylin Technologies Inc. Research Report at:
https://rdinvesting.com/news/?ticker=BYL.TO

Our Actionable Research on IntelliPharmaCeutics International Inc. (TSX:IPCI.TO), Nuvo Pharmaceuticals Inc. (TSX:NRI.TO), Oncolytics Biotech Inc. (TSX:ONC.TO) and Baylin Technologies Inc. (TSX:BYL.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com